Objectives: Reduced-frequency dosing strategies of anidulafungin may offer a more convenient way of providing adequate antifungal prophylaxis to patients at high risk of invasive fungal diseases. We aimed to provide the pharmacological rationale for the applicability of reduced-frequency dosing regimens.
Introduction
Azole antifungal drugs, specifically posaconazole and voriconazole, are currently used as primary and secondary antifungal prophylaxis in haematology patients experiencing prolonged neutropenia and specific cellular immune dysfunction, resulting from the disease itself and therapies used to treat them. 1 -4 Unfortunately, azole use frequently results in severe hepatotoxicity and liposomal amphotericin B shows dose-dependent renal toxicity. There are also concerns about the emergence of azole resistance among isolates of Aspergillus fumigatus. 5, 6 New strategies need to be identified to offer adequate prophylaxis to this group of vulnerable patients. Anidulafungin is a suitable candidate because of its more favourable safety profile. Furthermore, anidulafungin lacks drug -drug interactions, thereby improving the management of other drugs commonly used in the haematological setting. 
Methods
This open-label, Phase II study (ClinicalTrials.gov identifier: NCT01249820) was approved by the Ethics Committee of Radboud University Medical Center, Nijmegen in 2010 and was conducted in compliance with the Declaration of Helsinki. Patient informed consent was obtained before enrolment. From 2010 to 2012, adults aged 18 -65 years who were admitted to receive an allogeneic HSCT were eligible if they were to receive either myeloablative or reduced-intensity conditioning regimens to prepare for the partially T cell-depleted transplant or were to receive remission induction chemotherapy for AML or high-risk myelodysplastic syndrome (MDS). Each patient was managed with a four-lumen central venous catheter to allow the fourth lumen to be reserved exclusively for anidulafungin administration. Any signs or symptoms of invasive fungal disease (IFD) or the use antifungal drugs within the previous month was grounds for exclusion identical to previous studies. 12 This study was a two-cohort, open-label, Phase II study in which anidulafungin was administered intravenously the day following HSCT or directly after completing remission induction chemotherapy. Two cohorts of 10 patients each received 200 mg of anidulafungin every 48 h or 300 mg of anidulafungin every 72 h. All infusions were given at 8 A.M. at an infusion rate of 2 mg/min. This high infusion rate was tested to allow shorter infusions more appropriate for future use in the outpatient setting. Treatment was followed by a period of 14 days during which drug concentrations were measured daily and 1 week after the last dose to allow determination of terminal elimination.
Treatment protocol and supportive care
Remission induction chemotherapy consisted of idarubicin and cytarabine. 13 Myeloablative conditioning consisted of idarubicin, cyclophosphamide with either total body irradiation or busulfan for matched related donors. Matched unrelated donors received thymoglobulin and cyclophosphamide with either total body irradiation or busulfan. Reduced-intensity conditioning consisted of fludarabine, cyclophosphamide and melphalan. In allogeneic HSCT graft-versus-host disease prophylaxis consisted of cyclosporine A (1 mg/kg twice a day intravenously) starting on the day of HSCT.
Supportive care measures, including the use of antibacterial prophylaxis, management of the central venous catheter and the diagnostic approach for IFD, have previously been described in detail for the HSCT setting. 14, 15 Blood sampling Blood was obtained to determine sodium, potassium, chloride, calcium, inorganic phosphorus, total protein, albumin, glucose, total cholesterol, triglycerides, blood urea nitrogen, creatinine, uric acid, total bilirubin, alkaline phosphatase, AST, ALT, GGT and lactate dehydrogenase. Blood was also obtained to determine haemoglobin, leucocyte differential counts and platelet counts.
Vital signs, temperature, pulse, oxygen saturation and blood pressure were monitored immediately before starting the infusion and hourly for the first 4 h afterwards.
Blood samples were drawn into lithium heparin-containing tubes and centrifuged for 10 min at 1000 g (2500 rpm) within 30 min of collection. Plasma was aspirated and transferred in two plastic tubes and stored at 2808C.
Two pharmacokinetic curves were determined on days 5 (three doses) and 15 (eight doses) and on days 4 (two doses) and 13 (five doses) for the every 48 h regimen and the every 72 h regimen, respectively. Blood samples for the full pharmacokinetic analysis were taken at pre-defined times of t¼0 (pre-dose) and then at 0. 
Analytical assay
Anidulafungin samples were measured by UPLC with fluorescence detection. Samples were pre-treated using a protein precipitation procedure [acetonitrile/methanol (50/50) and formic acid (0.1%)]. A seven-point calibration curve with three quality control samples was used. All measurements were done in duplicate. The dynamic range of the assay was 0.008 -8.4 mg/L and the accuracy range (n ¼ 15), which was dependent on the concentration, was 94.2%-103.5%. The intraday precision varied between 0.9% and 1.8% and the interday precision was between 0.5% and 1.6%. Three freeze -thaw cycles did not impact the stability of anidulafungin. Recovery was 93% (coefficient of variation: 4%).
Pharmacokinetic model
The pharmacokinetic data were analysed using non-linear mixed-effects modelling with NONMEM 7.2 (Globomax, Hanover, MD, USA Discrimination between different models was achieved by comparing the objective function value (OFV; i.e. 22 log likelihood). A significance level of P,0.05, corresponding to a decrease in OFV of 3.8, was considered statistically significant. For diagnostic purposes, goodness-of-fit plots (GOF) were used. The CI of the parameter estimates, the correlation matrix and visual improvement of the individual plots were used to evaluate the models.
Pharmacokinetic models incorporating either one-, two-or threecompartment models with linear elimination were investigated. The first-order conditional estimation method with interaction was used throughout model development. Proportional, additive and combined additive and proportional residual error models were evaluated.
All covariates were plotted independently against the individual pharmacokinetic parameters and the weighted residuals of the model without covariates to visualize relations. Potential covariates were formally tested in the model as follows: for continuous covariates such as body weight [and derived parameters such as BMI or lean body mass (LBM)], the influence of the covariate on each pharmacokinetic parameter was tested using a linear or allometric function. Other covariates such as the use of concomitant drugs were modelled as dichotomous variables using linear functions. Statistical evaluation of the incorporated covariate relationships was performed by forward inclusion and backward deletion. A P value ,0.005 was applied to evaluate the covariates in the forward inclusion (an OFV value of ≥7.8 points), while the backward deletion procedure used a stricter criterion (OFV .10.83; P,0.001).
The covariates tested were body weight, BMI and LBM as well as renal function, bilirubin levels, white blood cell counts, absolute neutrophil counts, the liver function tests alkaline phosphatase, bilirubin, AST, ALT and GGT and the concomitant use of cyclosporine A, tacrolimus or prednisolone (as dichotomous variables). The Janmahasatian et al. formula was used to calculate the LBM 16 and renal function was estimated from the serum creatinine using Modification of Diet in Renal Disease formula.
Bootstrap analysis was used to validate the internal model for which the current datasets were resampled 1000 times to produce a new dataset of the same size containing a different combination of individuals. The parameter estimates were summarized in terms of mean values with their standard errors and were compared with the estimates obtained from the final model dataset. A visual predictive check (VPC) was done to assess the predictive performance of the model.
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Monte Carlo simulation
The pharmacokinetic model was then employed for the simulations to establish what exposure would be achieved using a wide variety of regimens. To build a valid dataset we used the population distribution of a cohort of 1706 AML/MDS and stem cell transplant patients from the haematology department [mean age (range) was 57 years (18-81), mean height (range) was 174.4 cm (135-204) and mean weight (range) was 76.4 kg (39 -145)]. The 1706 patients were replicated to a total of 18000 individuals with identical distribution of relevant parameters using R (http://www.r-project.org). We argued this would render a realistic distribution representing the average patient on a haematology ward. These 18000 virtual patients were equally distributed over six groups consisting of 3000 subjects each: licensed dose of anidulafungin at 200/100 mg with or without cyclosporine A; 200 mg of anidulafungin every 48 h with or without cyclosporine A; and 300 mg of anidulafungin every 72 h with or without cyclosporine A (dichotomous). A 'waste' compartment was defined to determine the cumulative AUC after 6 days of therapy. Day 6 was chosen as in this situation the same cumulative dose over time was given for the every 48 h regimen and the every 72 h regimen. The licensed regimen resulted in a cumulative dose of 700 mg instead of 600 mg for the every 48 h group and the every 72 h group.
Safety
All adverse events were recorded regardless of treatment or potential causal relationship to anidulafungin. Events involving adverse drug reactions, illness that developed during the study or exacerbations of pre-existing illnesses were considered adverse events. In addition, abnormal measurements (e.g. ECG changes and abnormal laboratory test results) that resulted in anidulafungin discontinuation or required intervention or diagnostic evaluation to assess the risk to the subject were also recorded as adverse events.
Results
Twenty-six patients gave written informed consent to participate in this study but only 20 patient episodes were fully evaluable. The every 48 h group (n¼ 10) consisted of 3 females and 7 males and the every 72 h group (n¼ 10) consisted of 2 females and 8 males. Their mean age was 55 years (range 21 -64) and their mean weight was 77 kg (range 52 -113). A detailed overview of the demographic characteristics of these 20 patients is given in Table 1 .
Pharmacokinetic model
All available drug concentrations were simultaneously modelled involving a total of 581 samples and 92 dosing records. A structural three-compartment model [CL and the volume of distribution of the central compartment (compartment 1) (V1) and two peripheral compartments (compartments 2 and 3) (V2 and V3)] best described the data. Both the GOF and the OFV improved compared with the two-compartment model. However, this model could not be retained when LBM was added because of a correlation between V1 and intercompartmental CL (Q1 -3). As a result, the model was simplified by equalizing V3 to V2 (a 2.5-compartment model). This did not result in any improvement. Hence, a two-compartment model was the final structural model. A combined error model was tested, but this did not improve the OFV or GOF. In the final model, the pharmacokinetic parameters were as follows: CL (without cyclosporine A) ¼ 1.49 L/h; CL (with cyclosporine A)¼1.02 L/h; V1¼31.8 L (for median LBM of 57 kg); V2¼23.1 L; and Q¼0.59 L/h. Parameter estimates of the structural model with interindividual variability are provided in Table 2 .
Covariate model
Treatment with cyclosporine A on CL and LBM on V1 were selected as significant covariates from the stepwise approach. Both covariates were modelled as linear variables. Allometric functions did not improve the GOF or OFV. The impact of other concomitant drugs on anidulafungin pharmacokinetics could not be determined as there was an insufficient number of patients using Brü ggemann et al.
these drugs to draw any valid conclusion. Apart from LBM and cyclosporine A, no parameter yielded a significant result. Liver function tests and renal function had no impact on either the V or CL of anidulafungin. In the three-compartment model, there was a correlation between the estimate of V1 and the intercompartmental CL between compartments 1 and 3 (Q1 -3) when LBM was added as a covariate. Setting V2 and V3 as identical compartments did not resolve this issue. Therefore, we chose to return to a two-compartment model rather than dropping LBM as a covariate on V1 as described in the structural model paragraph ( Figure S1 , available as Supplementary data at JAC Online).
Model validation
The results of the 1000 patient bootstrap confirmed the robustness of the model (Table 2) . VPC demonstrated the validity of the final covariate model (Figure 1a and b) .
Monte Carlo simulation
The (Table 3 and Figures 2 -4 ).
Safety
Three serious adverse events were recorded among the 26 patients. Patient A3 was diagnosed with a life-threatening bacterial sepsis 1 day after starting anidulafungin treatment. This patient dropped out of the study at that moment. Patient A12 died within 30 days after completion of the study (while having graft-versus-host disease and post-transplant lymphoproliferative disorder) due to a myocardial infarction. Patient B12 was admitted to the hospital within 30 days after completion of the study due to septic shock. None of the serious adverse events was considered related to the study drug. All other adverse events were mild, transient and resolved and it was not necessary to discontinue treatment. No ECG abnormalities were observed, there were no important laboratory abnormalities observed and the changes from baseline were moderate and not related to anidulafungin administration. The increased infusion rate of 2 mg/min was well tolerated by all the patients.
Fungal infections
None of the patients had a breakthrough fungal infection.
Discussion
From our study, we demonstrated that higher dosage of anidulafungin with less frequent administration resulted in comparable exposure over time (defined as cumulative exposure from day 1 to day 6) and that these less frequent administrations had identical exposure to daily dosing regimens. Furthermore, we demonstrated that dosages up to 300 mg resulted in linear pharmacokinetics. In the literature, dose-escalation studies to determine the linearity of pharmacokinetics were only investigated up to maintenance dosages of 130 mg once daily. 17 Taking the AUC/MIC as the pharmacokinetic/pharmacodynamic index, it is not unreasonable to assume that identical exposure using reduced-frequency dosing strategies will be as effective. In animal studies, dose escalation with increased dosing interval demonstrated the importance of the AUC/MIC and C max / MIC concentration-dependent indices. 9, 18, 19 In the clinical setting, however, this is not confirmed. Several studies have tried to use higher dosages of echinocandins to boost performance of these drugs against Candida species.
20, 21 Betts et al. 20 did not find any Brü ggemann et al.
significant gain when using 150 mg of caspofungin compared with regular dosing of 50 mg of caspofungin for invasive candidiasis. Contrary to the findings of Betts et al., 20 Andes et al.
21
demonstrated that micafungin at higher dosages with less frequent administrations resulted, although not significantly differently, in a trend towards better outcome in oesophageal candidiasis. If one accepts that C max /MIC is the driving parameter this would possibly mean that from a pharmacological view point a better efficacy can be expected. A drawback of higher dosages and subsequent C max has been associated with a paradoxical effect, but this has never been demonstrated in humans. 22 Another drawback of higher dosing is the chance of increased risk of toxicity. In the literature, reports have emerged on concentration-dependent side effects. 23 In our study, anidulafungin was well tolerated. Specifically, no infusion-related toxicity was noted even with the increased infusion rate of 2 mg/min (the regular rate is 1.1 mg/min). It must be noted that all administrations were done through a central venous catheter.
In addition to improved efficacy of reduced-frequency dosing strategies of echinocandins in in vivo models, it may also provide benefits in the setting of prophylaxis. No IFD occurred in the 20 patients [background incidence (invasive aspergillosis + candidaemia) 10%; unpublished data, J. P. Donnelly and W. J. F. M. Van Der Velden]. Frequently, the administration of azoles or CsA, cyclosporine A; q24h, licensed regimen of anidulafungin with a loading dose of 200 mg on the first day followed by a maintenance dose of 100 mg every 24 h as of day 2; q48h, 200 mg of anidulafungin every 48 h; q72h, 300 mg of anidulafungin every 72 h; median AUC, the median exposure achieved at the start of day 6 of therapy. Reduced-frequency dosing of anidulafungin 1171 JAC lipid formulations of amphotericin B are contraindicated due to specific organ dysfunction or due to drug interactions. In the future, a more prominent role due to emerging azole resistance can be attributed to the echinocandins 5, 6 and anidulafungin may thus provide a suitable alternative as prophylaxis in this cohort. The drawback of echinocandins is the limitation of intravenous administration. Less frequent dosing will provide a patient-friendly alternative to customary daily dosing regimens. Reduced-frequency dosing seems more feasible in the growing group of haematology patients that receive outpatient-based HSCT and chemotherapy. Moreover, patients requiring prolonged prophylaxis because of chronic graft-versus-host disease might be more easily managed and in an outpatient setting.
A number of papers have described the pharmacokinetics of anidulafungin at licensed dosing regimens. 24 -27 Our findings on pharmacokinetic parameters in the haematology population corroborate with the findings in other populations. Specifically, the work of Dowell et al. 27 and Liu and Mould, 25 who both used nonlinear mixed-effects modelling, showed similar findings to our work.
We found cyclosporine A to influence the CL of anidulafungin. If cyclosporine A was coadministered, the CL of anidulafungin was reduced resulting in a higher exposure. This has been described with a similar effect size by Dowell et al. 28 Next, weight and derived parameters were identified as a significant covariate on V1. Specifically, LBM correlated best with V1 in which higher LBM resulted in a larger volume of distribution for anidulafungin. The finding that body weight impacts Brü ggemann et al.
